Gastroenterology

How a beneficial gut microbe became a deadly pathogen

Researchers have figured out how specific strains of Enterococcus faecalis became a deadly pathogen, causing a series of deadly infections in the mid 1980s.

Antonio Gasbarrini (Cemad): ‘Great expectations for the next generation probiotics’

What characteristics will the probiotics of the future have? We asked Antonio Gasbarrini, director of CEMAD at the Policlinico Gemelli.

Many gut microbes could come from the mouth

Scientists have found that even in healthy people, many mouth microbes are able to reach the gut and colonize it. The study was published in the journal eLife.

Skin-dwelling fungus could play a role in inflammatory bowel disease

A common fungus found on skin may worsen symptoms of IBD in people with a particular genetic make-up, scientists report in Cell Host and Microbe.

New insights into how gut cells sense commensal microbes

Cells in the gut sense commensal microbes through receptors that trigger the production of inflammatory molecules and the activation of the immune system.

Differences in gut bacteria can distinguish between bowel diseases

The gut microbiota can be useful to distinguish between IBD and IBS. That's according to a study published in Science Translational Medicine.

Periodic low-calorie diet could reduce inflammatory bowel disease

A low-calorie, low-protein diet could help reduce the inflammation associated with IBD. That’s according to a study published in Cell Reports.

Probiotics and gastrointestinal infections in children: Gasbarrini comments on the negative results reported by the NEJM

Antonio Gasbarrini from the Gemelli Hospital in Rome explains how the modulation of the intestinal microbiota is entering medicine.

How beneficial gut microbes talk to intestinal cells

According to a study published in Science, some microbiota bacteria prevent immune activation by communicating with intestinal cells.

A microbiome approach to address NAFLD and intrahepatic cholestasis in pregnancy

MetaboGen is active in the field of live biotherapeutic products and on the study of liver diseases. We discussed their approach with Sara Malcus, CEO of the company.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top